A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Participants with Proliferative Lupus Nephritis or Immunoglobulin A Nephropathy

Grants and Contracts Details

StatusActive
Effective start/end date7/1/211/29/25

Funding

  • Syneos Health LLC: $69,880.00